Liglinra

Linagliptin, the active ingredient in Liglinra, is a dipeptidyl peptidase-4 (DPP-4) inhibitor presented as an oral tablet for oral use. It is prescribed to improve glycaemic control in adults with type 2 diabetes mellitus by enhancing endogenous incretin activity. It works by increasing insulin secretion after meals and reducing glucagon release.

GNH USA supplies Liglinra as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is distributed under strict regulatory oversight.

Liglinra (linagliptin) is used to manage blood glucose levels within the type 2 diabetes therapeutic pathway.

- Type 2 diabetes mellitus: improves overall glycaemic control and reduces HbA1c levels. - Monotherapy in type 2 diabetes: lowers fasting plasma glucose when used alone. - Combination therapy with metformin: enhances glucose‑lowering effect in patients inadequately controlled on metformin alone. - Adjunct to diet and exercise: assists patients in achieving target blood sugar alongside lifestyle measures.

Linagliptin may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient cranial pain. - Upper respiratory tract infection: symptoms such as cough and congestion. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain. - Severe allergic reactions: including rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or hepatitis. - Bullous pemphigoid: rare skin blistering disorder. - Severe hypoglycaemia: when combined with insulin or sulfonylureas.

When prescribing linagliptin, clinicians should consider several safety and monitoring points.

- Renal function: assess renal impairment before initiation and monitor periodically. - Hepatic function: evaluate liver enzymes in patients with existing liver disease. - Cardiovascular disease: use caution in patients with a history of heart failure. - Elderly patients: start at the recommended dose and monitor for adverse effects. - Pregnancy and lactation: avoid use unless the potential benefit justifies the risk, as safety data are limited. - Store at room temperature: keep below 25 °C in the original container, protect from moisture and light.

Linagliptin can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin effectiveness. - Insulin or sulfonylureas: concurrent use can precipitate severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics: may affect glucose homeostasis, requiring glycaemic monitoring. - NSAIDs: can impact renal function, especially in patients with pre‑existing kidney disease. - ACE inhibitors or ARBs: monitor blood pressure and renal parameters when combined. - Anticoagulants: observe for any changes in bleeding risk, although interaction is limited.